FRNM
NASDAQ HealthcareFreenome, Inc. - Common stock
Diagnostics & Research
Freenome, Inc. operates as a biotechnology company focused on developing blood-based tests for early cancer detection using artificial intelligence and multiomics technology. The company develops and provides blood-based tests for early cancer detection, including a test for colorectal cancer screening. It offers a multiomics platform that combines computational biology, machine learning, and multiple data types to identify biomarkers and detect various cancers. The company conducts clinical research programs, such as the PREEMPT CRC, Sanderson, and Vallania studies, to validate and expand its cancer detection tests to multiple cancer types. It collaborates with healthcare organizations and partners to advance clinical studies and enhance its product portfolio, including an autoantibody platform with additional biomarkers, and provides patient stratification and monitoring solutions using its multiomics technology. The company was founded in 2014 and is based in Brisbane, California.
๐ Market Data
| Price | $13.00 |
|---|---|
| Volume | 1,893,156 |
| Market Cap | 1.38B |
| Beta | 0.350 |
| RSI (14-Day) | 65.8 |
| 200-Day MA | $11.77 |
| 50-Day MA | $11.30 |
| 52-Week High | $14.47 |
| 52-Week Low | $9.95 |
| Price / Book | -0.26 |
๐ฏ Investment Strategy Scores
FRNM scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Over-Hyped (72/100) โ this strategy Overbought stocks (potential short candidates).
Lowest fit among scored strategies: ๐ Moon Shot (13/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find FRNM in your text
Paste any article, transcript, or post โ the tool will extract FRNM and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-08-17.